UCB reported a soft performance with a sales decline of 1% at CER in its Q1 18 trading update. Forex headwinds of 5% weighed further, resulting in a reported decline of 5% to €1.07bn. However, adjusting for the out-licensing of the allergy drug, Xyzal, which generated €56m in Q1 17, the CER growth came in at 4%. NB. All sales growth numbers are CER, unless specified otherwise. The five core products (accounting for ~78% of group sales) grew by 8% to €839m, led by the newbie Bri
26 Jun 2018
CVN starts to lose
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CVN starts to lose
UCB S.A. (UCB:WBO) | 0 0 1.1% | Mkt Cap: 13,141m
- Published:
26 Jun 2018 -
Author:
Kamla Singh -
Pages:
3
UCB reported a soft performance with a sales decline of 1% at CER in its Q1 18 trading update. Forex headwinds of 5% weighed further, resulting in a reported decline of 5% to €1.07bn. However, adjusting for the out-licensing of the allergy drug, Xyzal, which generated €56m in Q1 17, the CER growth came in at 4%. NB. All sales growth numbers are CER, unless specified otherwise. The five core products (accounting for ~78% of group sales) grew by 8% to €839m, led by the newbie Bri